舒泰神：注射用STSP-0601处于国家药监局正常审评流程中

Core Points - The company Shuotai Shen (300204.SZ) has provided an update regarding the conditional listing application for its injectable STSP-0601, which was accepted by the National Medical Products Administration (NMPA) in June 2025 and is currently undergoing the normal review process [2] - The priority review timeline for the listing registration application is set at 130 days, and the preliminary review by various professional departments has been completed, leading to a temporary suspension of the CDE's timing, which is part of the normal review process [2] - The review and approval process for STSP-0601 has not concluded, and stakeholders are encouraged to monitor future regular reports and project progress announcements for updates [2]